When good drugs go bad

Kathleen M. Giacomini, Ronald M. Krauss, Dan M. Roden, Michel Eichelbaum, Michael R. Hayden and Yusuke Nakamura
Additional contact information
Kathleen M. Giacomini: University of California, San Francisco
Ronald M. Krauss: Ronald M. Krauss is at the Childrens Hospital Oakland Research Institute
Dan M. Roden: Dan M. Roden is at the Vanderbilt University School of Medicine
Michel Eichelbaum: Michel Eichelbaum is at the Stuttgart Institut Klinische Pharmakologie
Michael R. Hayden: Michael R. Hayden is at the University of British Columbia
Yusuke Nakamura: Yusuke Nakamura is at the University of Tokyo.

Nature, 2007, vol. 446, issue 7139, 975-977

Abstract: How can we best reduce the risk of severe adverse reactions to marketed drugs? An international group of scientists argues that a global research network is needed to identify genetically at-risk populations.

Date: 2007
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/446975a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:446:y:2007:i:7139:d:10.1038_446975a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/446975a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().